Skip to main content
Sirona Biochem Corp. logo

Sirona Biochem Corp. — Investor Relations & Filings

Ticker · SRBCF ISIN · CA82967M1005 LEI · 549300CQE1Q87IG6W210 TSXV Real estate activities
Open in API
Filings indexed 367 across all filing types
Latest filing 2022-06-30 Regulatory Filings
Country CA Canada
Listing TSXV SRBCF

About Sirona Biochem Corp.

https://www.sironabiochem.com/

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery firm utilizing a proprietary platform technology to develop novel compounds. Through its wholly-owned French subsidiary, TFChem, the company specializes in stabilizing carbohydrate molecules, often via fluorination chemistry, to enhance their efficacy and safety for medical and cosmetic applications. Sirona Biochem's business strategy involves licensing or selling its patented compounds, such as the anti-aging and anti-wrinkle molecule GlycoProteMim™ (TFC-1326), to leading global pharmaceutical and cosmetic companies in exchange for up-front fees, milestone payments, and ongoing royalties.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2022-06-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a contract manufacturing agreement between Sirona Biochem and WuXi AppTec for producing a compound for clinical trials. It discusses the company's research, potential market, and future plans but does not contain financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any regulatory filing. It is an update on a business development related to product manufacturing and clinical trial preparation, which fits best under a general regulatory announcement or miscellaneous filing category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-06-22 English
News release - English.pdf
Regulatory Filings
2022-06-20 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a global exclusive licensing agreement between Sirona Biochem and Allergan Aesthetics. It discusses the terms of the agreement, the company's technology, and forward-looking statements. There is no indication of financial statements, regulatory filings, or detailed financial data. The content is typical of a Capital/Financing Update as it relates to licensing and commercial agreements impacting company financing and business development. The document length is about 4946 characters, which is consistent with a press release rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-06-16 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing significant corporate changes at Sirona Biochem Corp., including management and organizational restructuring, strategic review, and plans for growth and up listing. It does not contain financial statements, detailed financial performance data, or regulatory filings. It is not an earnings release, annual or interim report, or audit report. The focus is on management and organizational changes and strategic initiatives. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related corporate changes. The document length is 4625 characters, which is sufficient for a detailed announcement but not a full report. Confidence is high given the clear content and context.
2022-06-15 English
News release - English.pdf
Regulatory Filings
2022-04-11 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.